MARK CALLENDER: Open Payments
NPI 1942406616 · SLIDELL, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,623 in 76 payments from 16 companies in 2025. Trend: 2023 $1,003 · 2024 $1,020 · 2025 $1,623
Food & beverage: $1,336Education: $287
| Company | Payments | Amount |
|---|---|---|
| Galderma Laboratories, L.P. | 17 | $240 |
| Regeneron Healthcare Solutions, Inc. | 7 | $236 |
| UCB, Inc. | 10 | $209 |
| Janssen Biotech, Inc. | 6 | $181 |
| GENZYME CORPORATION | 10 | $160 |
| E.R. Squibb & Sons, L.L.C. | 5 | $142 |
| LEO Pharma Inc. | 5 | $112 |
| PFIZER INC. | 2 | $50 |
| ABBVIE INC. | 2 | $46 |
| Novartis Pharmaceuticals Corporation | 2 | $45 |
Products named: DUPIXENT, Bimzelx, NEMLUVIO, TREMFYA, Sotyktu, ADBRY, CIBINQO, SKYRIZI.
Industry payments across LA — which companies pay providers there.
